Business Context and Reporting Period
This Form 8-K Current Report for Palisade Bio, Inc. covers events occurring on June 5, 2023, and June 8, 2023, with the report filed on June 9, 2023. The filing details the transition of J.D. Finley from interim CEO to permanent CEO, the approval of supplemental equity grants, and the results of the Company's Annual Meeting of Stockholders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance, executive compensation, and equity plan amendments.
Material Changes and Corporate Actions
- Executive Compensation: J.D. Finley's annual base salary was increased from $490,000 to $542,000, and his target cash bonus was raised from 45% to 50% of base salary, effective June 1, 2023.
- Equity Grants:
- Employees: Approved 245,660 stock options and 112,030 restricted stock units (RSUs) vesting over three years.
- Directors: Approved grants for seven non-management directors, offering a choice between 5,160 options or a combination of 2,580 options and 1,880 RSUs, vesting over one year.
- Equity Plan Amendments: Stockholders approved amendments to the 2021 Equity Incentive Plan to increase the share pool by 708,072 shares and raise the annual evergreen increase from 4% to 7.5%. The 2021 Employee Stock Purchase Plan was also amended to increase the share pool by 109,944 shares and the annual evergreen increase from 1% to 2.5%.
Stockholder Voting Results
The Annual Meeting held on June 8, 2023, saw approximately 51.04% of outstanding shares present. Key voting outcomes included:
- Director Elections: James Neal, J.D. Finley, and Mary Ann Gray, Ph.D., were elected as Class III directors. Notably, Dr. Gray received an equal number of votes for and withheld (495,347 each).
- Accounting Firm: Ratification of Baker Tilly US, LLP was approved with 2,732,124 votes for versus 198,268 against.
- Equity Plan Amendments: Both the Equity Incentive Plan and Employee Stock Purchase Plan amendments were approved, though with significant opposition (approx. 46% against for the Equity Plan and 42% against for the Purchase Plan).
- Executive Compensation (Say-on-Pay): Approved on an advisory basis with 765,257 votes for versus 553,499 against.
- Compensation Vote Frequency: Stockholders voted for annual advisory votes on executive compensation (665,444 votes for 1-year frequency).
Investor Verification Checklist
- Verify the impact of the increased equity pool and evergreen provisions on future share dilution.
- Review the significant number of votes withheld for Director Mary Ann Gray, Ph.D., and the substantial "against" votes on the equity plan amendments and Say-on-Pay proposal.
- Confirm the total number of shares outstanding (5,781,919 as of the record date) and the specific vesting schedules for the new supplemental grants.
- Check subsequent filings for the Company's financial status, as this 8-K contains no revenue or cash flow data.